Latest by Canadian AIDS Treatment Information Exchange
Researchers at the British Columbia Centre for Excellence in HIV/AIDS along with other researchers in Vancouver have attempted to study the relative impact that ART, harm reduction or both can have on the spread of HIV.
A study has shown that a nurse-led intervention called AIMS (Adherence Improving self-Management Strategy) has had a measurable and significant effect on improving treatment success rates.
Bictegravir-containing regimens performed well over 48 weeks, with more than 90% of participants achieving a viral load less than 50 copies/mL.
The experimental integrase inhibitor being developed by Gilead Sciences is currently in phase III clinical trials.
The new nucleoside analogue GS-9131 may be useful as part of regimens for people who have strains of drug-resistant HIV.
A recent clinical trial found that doravirine was roughly equivalent in potency to darunavir-based regimens.
At the recent Conference on Retroviruses and Opportunistic Infections, researchers presented data about 5 new anti-HIV compounds in development.
A capsid inhibitor could affect three parts of HIV's life cycle and could be used by itself in the prevention of HIV infection. However, much work lies ahead before this drug's developer can be certain about that.
In a small cross-sectional study researchers found a link between the use of integrase inhibitors and the presence of low testosterone, but they may have inadvertently arrived at this conclusion.